📰 Neuronetics Inc News
Page 2 - Neuronetics Inc News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Neuronetics Inc. Real-time updates on events, politics, business and more.
April 10, 2024
Lack of early symptom improvement is not predictive of final responder statusMALVERN, Pa., April 10, 2024 -- Neuronetics, Inc. , a medical technology company focused on designing, developing, and...
March 28, 2024
As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
March 27, 2024
The U.S. FDA granted Neuronetics Inc. clearance for use of its Neurostar advanced therapy as an adjunctive treatment of major depressive disorder in patients aged 15 to 21, making it the first transcranial magnetic stimulation treatment (TMS) cleared for this age group, the company said.
March 27, 2024
William Blair reissued their market perform rating on shares of Neuronetics (NASDAQ:STIM – Free Report) in a research note published on Tuesday morning, RTT News reports. Separately, Piper Sandler reaffirmed an overweight rating and issued a $8.00 target price (up from $7.00) on shares of Neuronetics in a research note on Wednesday, March 6th. Read […]
March 27, 2024
This treatment is now the first and only TMS treatment that is FDA-cleared for this patient population.
March 26, 2024
Neuronetics (NASDAQ:STIM – Get Free Report)‘s stock had its “market perform” rating restated by William Blair in a note issued to investors on Tuesday, RTT News reports. Separately, Piper Sandler reiterated an “overweight” rating and issued a $8.00 target price (up previously from $7.00) on shares of Neuronetics in a research report on Wednesday, March […]
March 26, 2024
Neuronetics (NASDAQ:STIM – Get Free Report)‘s stock had its “market perform” rating restated by analysts at William Blair in a research note issued on Tuesday, RTT News reports. Separately, Piper Sandler reaffirmed an “overweight” rating and issued a $8.00 price target (up from $7.00) on shares of Neuronetics in a report on Wednesday, March 6th. […]
March 25, 2024
NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages 15 and olderMALVERN, Pa., March 25, 2024 -- Neuronetics, Inc. , a medical technology company focused on...
March 25, 2024
Neuronetics, Inc. (STIM) announced clearance from the FDA for NeuroStar Advanced Therapy for use as an adjunct for the treatment of major depressive disorder in adolescent patients aged 15-21.
March 25, 2024
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.